SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
Weight LossResearch-onlyVendors pending
Research-onlyVendors pendingFacts verified · 2026-05-25

HGH Fragment 176-191

Also known as Fragment 176-191, hgh fragment 176–191, hgh(176–191) · Wikipedia

HGH Fragment 176-191 is a synthetic 16-amino-acid peptide spanning the C-terminal lipolytic domain of human growth hormone. It is functionally identical to AOD-9604 (which adds an N-terminal tyrosine for radio-labelling) and is marketed in the research-chemical channel for fat loss and lipolysis support. Preclinical rodent work suggests it stimulates lipolysis and inhibits lipogenesis without engaging the GH receptor or affecting insulin sensitivity, but rigorous controlled human efficacy trials are essentially absent. Use is research-only and any weight-loss claims should be considered low-evidence.

—

best

price

—

per

mg

—

vendors

tracked

Research-only

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

HGH Fragment 176-191 corresponds to residues 176-191 of human growth hormone (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe). Preclinical rodent studies suggest it retains GH's lipolytic and anti-lipogenic activity on adipocytes without binding the GH receptor, sparing IGF-1 elevation and glucose-handling effects.

HGH Fragment 176-191 corresponds to residues 176-191 of human growth hormone (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe). Preclinical rodent studies suggest it retains GH's lipolytic and anti-lipogenic activity on adipocytes without binding the GH receptor, sparing IGF-1 elevation and glucose-handling effects. Proposed downstream effects include increased fat oxidation, elevated plasma glycerol, and reduced lipogenesis, with some evidence implicating beta3-adrenergic signaling in adipose tissue (Heffernan et al., Monash University). The precise receptor target in adipocytes remains undefined. Human pharmacology has not been characterized in published peer-reviewed trials.

Pharmacokinetic properties

Half-life

unknown (estimated minutes to a few hours; no rigorous human PK published)

Routes

subcutaneous

Bioavailability

Peptide; not orally bioavailable.

Amino-acid sequence

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Use & research dosing

Fat LossLipolysis SupportWeight Loss

No FDA-approved human dose exists. In self-experimentation protocols circulating in the research-chemical literature, 250-500 mcg is reported subcutaneously 1-3 times daily, often administered fasted (pre-cardio or pre-bed) on short cycles of 4-12 weeks. These protocols are anecdotal and have not been validated in controlled human efficacy trials for body-weight or fat-loss endpoints. Total daily doses up to 1500 mcg have been reported in bodybuilding forums. Research framing only.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Essentially the same molecule as AOD-9604 minus the N-terminal tyrosine, and shares the same evidence story: strong rodent lipolysis claims with weak-to-absent controlled human trial support. Popular in bodybuilding self-experimentation but the human fat-loss benefit is anecdotal. Frequently confused in vendor marketing with AOD-9604, which is the closely related analog that actually reached early human trials in obesity (without producing convincing weight-loss efficacy).

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • No completed controlled human efficacy trials for body-weight or fat-loss endpoints
  • Not FDA-approved; sold as a research chemical only
  • Pregnancy and breastfeeding - safety unknown
  • Avoid in active or suspected malignancy
  • Injection-site reactions reported
  • Quality, purity, and identity from gray-market vendors are highly variable
  • Long-term safety data in humans are absent
  • Confounded in marketing with AOD-9604; the molecules are nearly identical and share the same evidence gap

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/11713213/
  2. [02]https://pubmed.ncbi.nlm.nih.gov/11673763/

Facts verified

2026-05-25

Confidence

low

What this means

  • no controlled human efficacy trials
  • essentially identical to AOD-9604; shared evidence gap
  • rodent-only mechanism data

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.